A. Agil, R. Durán, F. Barrero, B. Morales, M. Araúzo et al., Plasma lipid peroxidation in sporadic Parkinson's disease. Role of the l-dopa, Journal of the Neurological Sciences, vol.240, issue.1-2, pp.31-36, 2006.
DOI : 10.1016/j.jns.2005.08.016

R. Bordet, S. Ridray, J. C. Schwartz, and P. Sokoloff, Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats, European Journal of Neuroscience, vol.63, issue.6, pp.2117-2123, 2000.
DOI : 10.1046/j.1460-9568.2000.00089.x

M. Carta, T. Carlsson, D. Kirik, and A. Björklund, Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats, Brain, vol.130, issue.7, pp.1819-1833, 2007.
DOI : 10.1093/brain/awm082

M. A. Cenci and M. Lundblad, -DOPA-Induced Dyskinesia in the Unilateral 6-OHDA Lesion Model of Parkinson's Disease in Rats and Mice, Curr Protoc Neurosci Chapter, vol.60, 2007.
DOI : 10.1002/0471142301.ns0925s41
URL : https://hal.archives-ouvertes.fr/in2p3-00025581

K. R. Chaudhuri and A. H. Schapira, Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment, The Lancet Neurology, vol.8, issue.5, pp.464-474, 2009.
DOI : 10.1016/S1474-4422(09)70068-7

L. Chen, Y. Ding, B. Cagniard, A. D. Van-laar, A. Mortimer et al., Unregulated Cytosolic Dopamine Causes Neurodegeneration Associated with Oxidative Stress in Mice, Journal of Neuroscience, vol.28, issue.2, pp.425-433, 2008.
DOI : 10.1523/JNEUROSCI.3602-07.2008

A. Ciesielska, N. Sharma, J. Beyer, J. Forsayeth, and K. Bankiewicz, Carbidopa-Based Modulation of the Functional Effect of the AAV2-hAADC Gene Therapy in 6-OHDA Lesioned Rats, PLOS ONE, vol.747, issue.5 Suppl 2, 2015.
DOI : 10.1371/journal.pone.0122708.s001

K. P. Datla, S. B. Blunt, and D. T. Dexter, nigrostriatal lesions, Movement Disorders, vol.66, issue.3, pp.424-434, 2001.
DOI : 10.1002/mds.1091

D. Lau, L. M. Breteler, and M. M. , Epidemiology of Parkinson's disease, The Lancet Neurology, vol.5, issue.6, pp.525-535, 2006.
DOI : 10.1016/S1474-4422(06)70471-9

D. Devos, D. French, and . Group, Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease, Movement Disorders, vol.50, issue.7, pp.993-1000, 2009.
DOI : 10.1002/mds.22450

J. G. De-yebenes, S. Fahn, S. Lovelle, V. Jackson-lewis, P. Jorge et al., Continuous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson???s disease, Mov. Disord, vol.2, pp.143-158, 1987.
DOI : 10.1007/978-3-7091-8954-2_13

S. Drapier, A. Eusebio, B. Degos, M. Vérin, F. Durif et al., Quality of life in Parkinson???s disease improved by apomorphine pump: the OPTIPUMP cohort study, Journal of Neurology, vol.5, issue.6, pp.1111-1119, 2016.
DOI : 10.1007/s00415-016-8106-3
URL : https://hal.archives-ouvertes.fr/hal-01301510

I. Espadas, S. Darmopil, E. Vergaño-vera, O. Ortiz, I. Oliva et al., L-DOPA-induced increase in TH-immunoreactive striatal neurons in parkinsonian mice: Insights into regulation and function, Neurobiology of Disease, vol.48, issue.3, pp.271-281, 2012.
DOI : 10.1016/j.nbd.2012.07.012
URL : https://digital.csic.es/bitstream/10261/61517/1/accesoRestringido.pdf

S. Fahn, . Parkinson-study, and . Group, Does levodopa slow or hasten the rate of progression of Parkinson???s disease?, Journal of Neurology, vol.41, issue.S4, pp.37-42, 2005.
DOI : 10.1007/s00415-005-4008-5

F. Fornai, G. Battaglia, M. Gesi, F. S. Giorgi, F. Orzi et al., Time-course and dose???response study on the effects of chronic l-DOPA administration on striatal dopamine levels and dopamine transporter following MPTP toxicity, Brain Research, vol.887, issue.1, pp.110-117, 2000.
DOI : 10.1016/S0006-8993(00)02999-1

V. Francardo, A. Recchia, N. Popovic, D. Andersson, H. Nissbrandt et al., Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease, Neurobiology of Disease, vol.42, issue.3, pp.327-340, 2011.
DOI : 10.1016/j.nbd.2011.01.024

O. Gershanik and P. Jenner, Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson???s disease, European Journal of Neurology, vol.68, issue.Suppl. 4, pp.1502-1508, 2012.
DOI : 10.1111/j.1468-1331.2011.03593.x

R. Hargraves and W. J. Freed, Chronic intrastriatal dopamine infusions in rats with unilateral lesions of the substantia nigra, Life Sciences, vol.40, issue.10, pp.959-966, 1987.
DOI : 10.1016/0024-3205(87)90315-8

T. G. Hastings, D. A. Lewis, and M. J. Zigmond, Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections., Proceedings of the National Academy of Sciences, vol.93, issue.5, pp.1956-1961, 1996.
DOI : 10.1073/pnas.93.5.1956

M. K. Horne, E. G. Butler, B. S. Gilligan, J. Wodak, R. J. Stark et al., Intraventricular infusion of dopamine in Parkinson's disease, Annals of Neurology, vol.2, issue.6, pp.792-794, 1989.
DOI : 10.1002/ana.410260620

B. S. Jeon, V. Jackson-lewis, and R. E. Burke, 6-Hydroxydopamine Lesion of the Rat Substantia Nigra: Time Course and Morphology of Cell Death, Neurodegeneration, vol.4, issue.2, pp.131-137, 1995.
DOI : 10.1006/neur.1995.0016

Z. Jia, H. Zhu, B. R. Misra, Y. Li, and H. P. Misra, Dopamine as a Potent Inducer of Cellular Glutathione and NAD(P)H:Quinone Oxidoreductase 1 in PC12 Neuronal Cells: A Potential Adaptive Mechanism for Dopaminergic Neuroprotection, Neurochemical Research, vol.378, issue.112, pp.2197-2205, 2008.
DOI : 10.1007/s11064-008-9670-4

J. S. Kroin, L. C. Kao, T. J. Zhang, R. D. Penn, H. L. Klawans et al., Dopamine distribution and behavioral alterations resulting from dopamine infusion into the brain of the lesioned rat, Journal of Neurosurgery, vol.74, issue.1, pp.105-111, 1991.
DOI : 10.3171/jns.1991.74.1.0105

C. Laloux, M. Petrault, C. Lecointe, D. Devos, and R. Bordet, Differential susceptibility to the PPAR-?? agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson's disease, Pharmacological Research, vol.65, issue.5, pp.514-522, 2012.
DOI : 10.1016/j.phrs.2012.02.008

B. Nair and A. R. Elmore, Cosmetic Ingredients Review Expert Panel Final report on the safety assessment of sodium sulfite, potassium sulfite, ammonium sulfite, sodium bisulfite, ammonium bisulfite, sodium metabisulfite and potassium metabisulfite, Int. J. Toxicol, vol.22, issue.2, pp.63-88, 2003.

C. W. Olanow, J. A. Obeso, and F. Stocchi, Drug Insight: continuous dopaminergic stimulation in the treatment of Parkinson's disease, Nature Clinical Practice Neurology, vol.20, issue.7, pp.382-392, 2006.
DOI : 10.1038/ncpneuro0222

M. Olsson, G. Nikkhah, C. Bentlage, and A. Björklund, Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test, J. Neurosci, vol.15, pp.3863-3875, 1995.

C. A. Paladini and J. Roeper, Generating bursts (and pauses) in the dopamine midbrain neurons, Neuroscience, vol.282, pp.109-121, 2014.
DOI : 10.1016/j.neuroscience.2014.07.032

T. Schallert, S. M. Fleming, J. L. Leasure, J. L. Tillerson, and S. T. Bland, CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury, Neuropharmacology, vol.39, issue.5, pp.777-787, 2000.
DOI : 10.1016/S0028-3908(00)00005-8

N. Venna, T. D. Sabin, J. I. Ordia, and V. H. Mark, Treatment of Severe Parkinson's Disease by Intraventricular Injection of Dopamine, Stereotactic and Functional Neurosurgery, vol.47, issue.1-2, pp.62-64, 1984.
DOI : 10.1159/000101204